AstraZeneca and Daiichi Sankyo's HER2-directed antibody-drug conjugate Enhertu (trastuzumab deruxtecan) already has accelerated approval as a second-line treatment for HER2-mutated NSCLC and is dosed ...

Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

Enhertu (fam-trastuzumab deruxtecan-nxki) has received FDA approval for HR-positive, HER2-low, HER2-ultralow metastatic breast cancer.

Daiichi Sankyo had opposed the open offer made in 2018 after Northern TK Venture had acquired a 31% stake in Fortis. NTK had then filed a lawsuit against Daiichi Sankyo in November 2023.

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this ...

Malaysia's IHH Healthcare Berhad has announced that its Singaporean subsidiary, Northern TK Venture Pte Ltd (NTK), has raised its damage claim against Japan's Daiichi Sankyo to JPY 199.8 billion ...

Malaysia's IHH Healthcare said on Thursday its unit is seeking compensation of up to 109.3 billion rupees ($1.25 billion) from Japan's Daiichi Sankyo for its stake buy in India's Fortis Healthcare.

New Delhi, Feb 6 (PTI) Malaysia's IHH Healthcare Berhad on Thursday said its Singaporean arm Northern TK Venture Pte Ltd has increased the claim for damage from Japan's Daiichi Sankyo to up to JPY 199 ...

The company’s PATHWAY HER2 antibody test—used to help screen patients for treatment with Enhertu (trastuzumab deruxtecan-nxki), the antibody-drug conjugate jointly developed by Daiichi Sankyo ...

Approval of Enhertu was granted to AstraZeneca and Daiichi Sankyo. More Information ...